Twist Bioscience launches new products as stock falls 13.4%

Traders Union
All News
Business & Wealth
Companies
Twist Bioscience stock falls 13.4% today

Highlights

Shares of Twist Bioscience are down 13.4% on the day at $150.17.
Twist Bioscience introduced MRD Express and Express Screening Antibodies to accelerate high-throughput antibody discovery for AI-driven workflows.
36 of 48 analysts covering the stock rate it a buy, with a median price target of $188.5.

Twist Bioscience announced in its October newsletter that it has launched new products, including MRD Express and Express Screening Antibodies. The company says Express Screening Antibodies enables high-throughput assessment of thousands of antibodies per day to support AI and machine learning discovery workflows, with turnaround times starting in as little as five days, according to Twist Bioscience. Twist Bioscience operates in biotechnology, employs 979 people and holds a market value near $8.47 billion on trailing revenue of $431.7 million.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish structure split as price drops below MA-20 and overbought signals build

Price lost the MA-20 at $155.76 during the session after previously closing above it. The daily move runs against a broader bullish chart structure, with shares sitting below both the MA-20 and MA-50 but still above the MA-200, creating a split picture for trend direction. Stoch RSI is in overbought territory, a stretched reading that limits room for further upside. The nearest resistance is at the MA-50, which stands at $152.78.

Upside odds hold above the downside case as traders watch MA-50 close

Traders should watch for a close above $152.78 to indicate buyers are willing to follow through. Earlier in the session, price lost the MA-20 at $155.76 after having closed above that level. Despite a sharp move higher over the past week without a sustained trend, the upside probability for the coming trading week is more than 80%, with downside risk seen at less than 20%. The expected trading range is $131.45 to $168.88. A drop below $136.44 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Previously it was reported that Twist Bioscience’s new viral research product launch reinforced a constructive longer-term technical outlook. The current article signals a shift, as the stock’s significant daily drop and break below short-term moving averages introduce downside risk, making a close above $152.78 the immediate level for traders to monitor for signs of renewed strength.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.